Harnessing innate mechanisms of gene activation, small activating RNA (RNAa) therapeutics are a revolutionary new class of medicines that can restore or boost normal function of genes in patients’ cells. We are advancing a proprietary pipeline of new medicines with an initial focus on genetic medicine, while collaborating with leading pharmaceutical companies to apply our technology platform across a broad range of other therapeutic areas.
NEW CLASS OF MEDICINES
Small activating RNAs are an entirely new class of medicines with potential to offer transformational benefits to patients across a wide range of diseases.
CLINICAL STAGE PLATFORM
We have developed a systematic approach to take new saRNA medicines from an idea to patients in a clinical trial in just 2 years.
Driving our platform are a group of passionate scientists, drug developers, doctors and entrepreneurs shaped by experience in oligonucleotide therapeutics, oncology and immunology.